Ophthalmology myCME Courses

Ophthalmology CME/CE Courses

myCMEYour search for high-quality, complimentary CME/CE stops right here. The courses below are presented by myCME, the continuing education engine in Haymarket Medical Network’s (HMN) expanding portfolio of clinical websites. Below you’ll find practice-relevant courses that carry valuable CME/CE credit. Simply click any link to get started earning credit on myCME.

Featured Courses

Safe and Effective Use of MS Disease-Modifying Therapies During the COVID-19 Crisis

Safe and Effective Use of MS Disease-Modifying Therapies During the COVID-19 Crisis | myCME

AMA PRA Category 1 Credit(s)TM
As coronavirus disease 19 (COVID-19) has become a worldwide issue, being declared a pandemic by the World Health Organization, it affects many aspects of healthcare. Specifically, many patients with multiple sclerosis (MS) take medications that alter or suppress their immune system. Rightly, they and their treatment team are concerned about the safest, but also most effective treatment strategy that considers both MS and the risk of COVID-19.
Implementing a Shingles Protocol in Specialty Practices

Implementing a Shingles Protocol in Specialty Practices | myCME

AMA PRA Category 1 Credit(s)TM, CE for Pharmacists
This CMEOCast podcast focuses on best practices to increase vaccine uptake and completion in vaccine-eligible patients and those at risk who present to specialty settings. The podcast will address ideal strategies to store and administer RZV, counseling patients on the extensive burden associated with shingles, and the benefits and potential risks of vaccination.
2021 Multiple Sclerosis Updates: A Focus on New and Emerging Therapies, Best Practices in Clinical Management and Key Considerations During the COVID-19 Era

2021 Multiple Sclerosis Updates: A Focus on New and Emerging Therapies, Best Practices in Clinical Management and Key Considerations During the COVID-19 Era | myCME

AMA PRA Category 1 Credit(s)TM
Although the multifactorial causes of multiple sclerosis (MS) are not known, an improved understanding of the neuroimmunologic pathogenesis has led to the development of a wide variety of disease-modifying treatments (DMTs). While there is no cure for MS, these treatments can reduce disease activity and delay MS progression and disability.
An Update on COVID-19 and MS: Disease-Modifying Therapies and COVID Vaccines

An Update on COVID-19 and MS: Disease-Modifying Therapies and COVID Vaccines | myCME

AMA PRA Category 1 Credit(s)TM
This program provides an update on our previous activity titled: Safe and Effective Use of MS Disease-Modifying Therapies During the COVID-19 Crisis by discussing updates on the impact of various MS disease-modifying therapies and risk of COVID infection, updates on the vaccines approved and in development to prevent COVID-19 infection, and special consideration for vaccine administration for patients on MS disease-modifying therapies.
Immune Dysfunction in Multiple Sclerosis: Modern Considerations in Treatment and Management

Immune Dysfunction in Multiple Sclerosis: Modern Considerations in Treatment and Management | myCME

AMA PRA Category 1 Credit(s)TM, CNE Contact Hour(s), CE for Pharmacists
This activity provides an overview of the role of the innate and adaptive immune systems in the development and progression of multiple sclerosis (MS), while exploring the therapeutic implications of immune dysfunction. MS immunotherapies are reviewed, with a focus on their mechanisms of action and immune-related toxicities. Patient case studies are included to illustrate considerations in the selection and sequencing of therapy and the management of immune-related toxicities.
Next-Generation S1P Modulators in MS Management

Next-Generation S1P Modulators: Clinical Implications of Higher Selectivity in MS Management | myCME

AMA PRA Category 1 Credit(s)TM, ANCC Contact Hour(s), CE for Pharmacists
Multiple sclerosis (MS) management requires balancing the benefits of medications aimed at inhibiting inflammation and immunosuppression or immunomodulation against the risks of serious adverse effects and other drawbacks, such as the inconvenience and discomfort of infusions or injections. In this roundtable discussion, 2 experts in MS management review current and investigational treatments with a focus on newer sphingosine 1-phosphate (S1P) receptor modulators.
When and How to Switch Therapies in MS: Neurology Guideline Implementation and Expert Recommendation

When and How to Switch Therapies in MS: Neurology Guideline Implementation and Expert Recommendation | myCME

AMA PRA Category 1 Credit(s)TM
Medications such as immunomodulatory and immunosuppressive disease-modifying therapies (DMTs) can delay this damage and slow the resulting progressive phase, thus helping maintain quality of life for patients with Multiple Sclerosis. To make an informed decision, clinicians need to understand the rationale behind medication choices and the risks and benefits of DMTs available.
Advances in Sustained Delivery of Anti-VEGF Therapy: Prepare for Practice Change

Advances in Sustained Delivery of Anti-VEGF Therapy: Prepare for Practice Change | myCME

AMA PRA Category 1 Credit(s)TM
Join Drs. Arshad M. Khanani and Carl D. Regillo, as they discuss current and emerging strategies for effective and durable treatment of neovascular retinal diseases. The expert faculty will present exciting new data to inform optimal use of currently available intravitreal antivascular endothelial growth factor (anti-VEGF) therapies, as well as the science and surgical techniques related to unprecedented new options for sustained delivery of anti-VEGF therapy that are coming soon.

Click for More Ophthalmology Courses